Clin2
NCT07030478Possibly a fitNot yet recruiting

Testing EP0089 for advanced solid tumors

Solid CancersSolid Tumours

Part of Cancer clinical trials.

This study tests an experimental drug called EP0089 for people with advanced solid tumors that haven't responded to other treatments. It aims to find a safe dose and see if it helps control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
190 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older (or 19 in South Korea) and have a solid tumor that has spread or cannot be removed, and standard treatments either don't exist or have stopped working.
  • You are in good enough health to be up and about (ECOG score 0 or 1) and expected to live more than 3 months.
  • You have at least one tumor that can be measured on scans or exam.
  • You must not have active cancer that has spread to the brain (unless treated and stable), or certain neurological or autoimmune conditions.
  • You cannot be taking high-dose steroids (more than 10 mg of prednisone daily) or have had a severe allergic reaction to similar antibodies in the past.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06205082Enrolling by invitation· Phase 1
Testing LIT-00814 tablets for advanced solid tumors

This trial tests an experimental oral tablet (LIT-00814) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and to find the best dose.

Beijing, Beijing Municipality
NCT07163325Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.

Brussels
NCT06990698Recruiting· Phase 1
Testing FP008 in advanced solid tumors

This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.

Wuhan, Hubei
NCT07660432Recruiting· Phase 1
Testing SIM0689 for advanced solid tumors

This study tests a new drug called SIM0689 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective, and researchers will look at tumor samples to understand which patients might benefit most.

Fuzhou, Fujian
NCT06718621Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.

Shanghai, Shanghai Municipality
NCT06801470Recruiting· Phase 1
Testing the safety of CD-001 in advanced solid tumors

This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.

Tianjin

Hear when a new Solid Cancers trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.